Built around

how you work.

Sleuth replaces patchworks of database subscriptions, consulting engagements, and internal spreadsheets — whether your team runs the analysis or ours does.

Studio
Concierge
API

Hi! I'm Sleuth Copilot,your biopharma research assistant.

I can help you analyze clinical trials, understand drug mechanisms, explore competitive landscapes, and more.

Recent Updates
Executive Summary
PD-L1 × VEGF landscape: post-HARMONi-2 moves was completed
×
Dataset
Phase 1 & 2a clinical trials for NSCLC was completed
×
Dataset
Auto-inflammatory landscape: key assets was completed
×
Version: v1
A — @IntersectionB — @WhyC — @De-riskedD — @ConfidenceE — @Key assets
Masked CD3 TCEsTargets off-tumor toxicityCD3 TCE validatedHighDR510, WTX-1011
Logic-gated AND designsClean-TAA durability gapCD3 redirection validatedMediumSEECR-T, ZW209
CD16A innate engagersAFM24 tolerability signalCombination strategiesMediumAFM24, GTB-3550
BCMA × GPRC5D bispecificsBetter vs teclistamab monoDual-antigen de-riskedHighAlnuctamab, ABBV-383
Source
Dataset
Insight
Dataset
T-Cell Engagers (TCEs)
Completev2
Updated yesterday
Dataset
Whitespace × de-risking
Completev2
Updated 2h ago
Pinned Item
Whitespace, post-Pfizer
Sleuth Studio
—×
Q3 TCE Landscape Summary
Dataset
Presentation
Asset Distribution by Modality
SM
Cell
Ab
ADC
Deg
Key Findings
Export to PDF
Share
Q3 TCE Landscape

Small molecule leads the modality mix

Asset distribution across 5 modalities

n = 1,247
Small Molecule
Cell Therapy
Ab / Bispecific
ADC
Degrader
Sleuth Concierge
Sleuth studio

Your team’s strategic analysis environment

Your projects, datasets, and insights live in one place. Always current, always ready to iterate.

Your analytical home base

Ask complex biopharma questions in plain language. Receive structured, evidence-backed analyses built on the Sleuth platform.

Eliminate data wrangling

Get structured datasets bespoke to your questions. Refine them without new data dumps.

Trace every conclusion to source

Click any data point to see the underlying evidence, from FDA labels to clinical publications.

Analyses that evolve with you

Refine, update, and steer your work as new evidence emerges or your questions sharpen.

Presentation-ready from the start

Charts, summaries, and structured views you can drop straight into a deck — no reformatting required.

Sleuth CONCIERGE

Embedded,
Not outsourced.

For high-stakes decisions where human judgment matters — an analytical
team that works inside the Sleuth platform alongside yours. Without six-week timelines or seven-figure invoices.

Capacity on demand.

When the board wants a new landscape by end of week or a diligence window opens overnight, Sleuth scales your team immediately.

No handoffs.

Sleuth doesn’t deliver a deck and disappear. You’re in the room — scoping together, pressure-testing assumptions, redirecting as questions sharpen.

Defensible decisions.

Billion-dollar decisions require human judgment. Sleuth's biopharma analysts deliver opinionated, board-ready work — not a data dump with a disclaimer.

No ramp-up.

Traditional consulting spends most of its time gathering context and cleaning data before the real thinking starts. Sleuth skips that step and goes straight to strategizing.

Case study

Shaping a decade
of growth

Daiichi Sankyo

Sleuth delivered a comprehensive peer benchmarking analysis in days. Every competitor's pipeline classified by modality, target, and stage. Interpreted in the context of Daiichi Sankyo's strategy.

Read Full Case Study

Example Concierge Deliverables

China Biopharma Landscape: 18,000+ Assets, 335 Deals, and the Gaps

The translation gap, not the innovation gap, is the binding constraint. 18,000+ Chinese assets, 335 out-licensing deals since 2021, and ~$18B in disclosed upfronts.
View Analysis

STAT6 Dermatology Landscape: 39 Programs, One Clinical Leader

39 STAT6-targeting programs mapped. Only Kymera's KT-621 has reached the clinic in dermatology. 23 competitors remain stalled at preclinical.
View Analysis

mTOR Non-Oncology Partnership Landscape: 144 Assets Mapped

144 mTOR pathway assets targeting non-oncology indications. 67% of clinical assets remain unpartnered despite Phase II-III maturity.
View Analysis
Sleuth API

Plug into the intelligence layer.

Access Sleuth's knowledge base, structured datasets, and analytical capabilities programmatically. Build biopharma intelligence into the tools your team already uses.

Get in Touch

Find the right fit for your team

Every team works differently. Book a demo and we’ll walk through Studio, Concierge, and API to find the right set up for your company’s stage and how your team makes decisions.

Book a Demo
Read FAQ